These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31059726)

  • 21. 7 - Terapia Nella Malattia In Progressione E Metastatica.
    Tumori; 2018 Mar; 104(2_suppl):S27-S31. PubMed ID: 29893176
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.
    Garje R; Chau JJ; Chung J; Wanat K; Zakharia Y
    J Immunother; 2018 Jan; 41(1):42-44. PubMed ID: 29111983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
    BJU Int; 2024 Jul; 134(1):4-5. PubMed ID: 38889995
    [No Abstract]   [Full Text] [Related]  

  • 24. Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice.
    Parikh RB; Galsky MD; Gyawali B; Riaz F; Kaufmann TL; Cohen AB; Adamson BJS; Gross CP; Meropol NJ; Mamtani R
    Oncologist; 2019 Jun; 24(6):e397-e399. PubMed ID: 30944183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma.
    Schvartsman G; Perez K; Sood G; Katkhuda R; Tawbi H
    Ann Intern Med; 2017 Sep; 167(5):361-362. PubMed ID: 28761949
    [No Abstract]   [Full Text] [Related]  

  • 27. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
    Med Lett Drugs Ther; 2017 Feb; 59(1515):e40-e41. PubMed ID: 28222066
    [No Abstract]   [Full Text] [Related]  

  • 28. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
    Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
    [No Abstract]   [Full Text] [Related]  

  • 29. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Goldstein DA; Bilal U; Prasad V
    Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
    [No Abstract]   [Full Text] [Related]  

  • 30. Immune checkpoint inhibitors: a new frontier in bladder cancer.
    Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
    World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
    Kobayashi Y; Iijima K; Kondo Y; Yamamoto K; Sekijima Y
    Acta Neurol Belg; 2024 Jun; 124(3):1063-1065. PubMed ID: 38010574
    [No Abstract]   [Full Text] [Related]  

  • 32. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.
    Ansell SM
    Lancet Haematol; 2019 Jan; 6(1):e2-e3. PubMed ID: 30612711
    [No Abstract]   [Full Text] [Related]  

  • 33. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
    Galsky MD
    Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
    [No Abstract]   [Full Text] [Related]  

  • 34. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
    Janisch F; Rink M; Shariat SF
    BJU Int; 2020 Jun; 125(6):753-755. PubMed ID: 32011069
    [No Abstract]   [Full Text] [Related]  

  • 35. Diaphragm involvement in immune checkpoint inhibitor-related myositis.
    Sekiguchi K; Hashimoto R; Noda Y; Tachibana H; Otsuka Y; Chihara N; Shiraishi Y; Inoue T; Ueda T
    Muscle Nerve; 2019 Oct; 60(4):E23-E25. PubMed ID: 31323130
    [No Abstract]   [Full Text] [Related]  

  • 36. The best treatments to use after checkpoint inhibition in melanoma.
    McArthur G
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):242-245. PubMed ID: 28591097
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Grimm MO; Leucht K
    Eur Urol; 2021 Mar; 79(3):429-430. PubMed ID: 33148473
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Gakis G
    Eur Urol; 2021 May; 79(5):702. PubMed ID: 33390284
    [No Abstract]   [Full Text] [Related]  

  • 39. Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy.
    Samaha H; Samaha R; Sarkis J; Kattan J
    Immunotherapy; 2021 Mar; 13(4):271-275. PubMed ID: 33397137
    [No Abstract]   [Full Text] [Related]  

  • 40. Pembrolizumab associated hemophagocytic lymphohistiocytosis.
    Shah D; Shrestha R; Ramlal R; Hatton J; Saeed H
    Ann Oncol; 2017 Jun; 28(6):1403. PubMed ID: 28368439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.